标记在内的PSMA向配体与不同的白蛋白结合剂的结构-亲缘关系-药理动力学关系[111]
Keisei Yamaguchi1, Nobuki Kazuta1, Shohei Tsuchihashi1
1Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan.
Nuclear medicine and biology
|August 17, 2024
概括
修改针对PSMA的放射性对象的白蛋白结合剂 (ALB) 部分会显著影响它们的药理动力学和瘤积累. 优化ALB部分对于开发有效的前列腺癌PSMA向疗法至关重要.
科学领域:
- 核医学是一种核医学.
- 放射性药物化学 放射性药物化学
- 在瘤学瘤学.
背景情况:
- 前列腺特异性膜抗原 (PSMA) 是转移性割抵抗性前列腺癌治疗的关键标.
- 针对PSMA的放射性链体,如PSMA-NAT-DA1 (PNT-DA1),正在开发中,以提高治疗疗效.
- PNT-DA1中的白蛋白结合剂 (ALB) 部分影响其药理动力学特性,但其化学修饰效应尚未得到充分研究.
研究的目的:
- 调查白蛋白结合剂 (ALB) 部分的化学修饰与针对PSMA的放射性连接体的药理动力学之间的关系.
- 设计,合成和评估新的[111In]In-PNT-DA1类似物,使用各种ALB部分.
- 评估ALB部分变异对体外稳定性,蛋白质结合和体外组织分布的影响.
主要方法:
- 通过配体置换合成四种[111In]In-PNT-DA1类似物,具有不同的ALB部分.
- 在实验室中评估了小鼠血中放射性的稳定性,对人血清白蛋白 (HSA) 的亲和力,以及与小鼠血蛋白的结合.
- 在实验室中评估PSMA结合亲和力和体内生物分布研究LNCaP瘤携带裸体小鼠.
主要成果:
- 所有合成的[111In]In-PNT-DA1类似物在小鼠血中表现出高的放射化学产量,纯度和稳定性.
- 在不同的ALB部分中观察到HSA结合亲和力的显著变化.
- 药理动力学根据ALB部分显著变化,较高的瘤AUC与增加的血液保留相关.
结论:
- 选择ALB部分对PSMA向放射性对象的药理学行为产生关键影响.
- 优化ALB部分可以增强PSMA向放射性对象的瘤积累.
- 这项研究为通过微调ALB组件开发更有效的PSMA向放射治疗提供了基础.
相关概念视频
01:29Drug Distribution: Plasma Protein Binding
5.5K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
5.5K
01:20Factors Affecting Protein-Drug Binding: Protein-Related Factors
135
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
135
01:18Factors Affecting Protein-Drug Binding: Drug-Related Factors
87
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
87
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
45
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
45
01:30Drug Binding to Blood Components
125
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
125
01:13Physiological Pharmacokinetic Models: Assumption with Protein Binding
36
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
36